Medical School, Free University of Berlin, Berlin, Germany, and University of London, London, England
Dr. med. (research doctorate), Free University of Berlin, Berlin, Germany
Postdoctoral Fellow, Department of Cell Biology, Baylor College of Medicine, Houston, Texas
Habilitation in Pharmacology and Toxicology, University of Zurich, Zürich, Switzerland
Medical Specialist in Pharmacology and Toxicology, Chamber of Physicians, Berlin, Germany
Director of the Laboratory of Genetic Neuropharmacology at McLean Hospital, Belmont, Mass., and Lecturer, Associate Professor, and Full Professor at Harvard Medical School, Boston, Mass.
External Lecturer of Pharmacology and Toxicology, Swiss Federal Institute of Technology (ETH), Zürich, Switzerland
Senior Scientist, Lecturer and Assistant Professor of Molecular Neuropharmacology, Institute of Pharmacology and Toxicology, University of Zurich Medical School, Zürich, Switzerland
Instructor, Department of Cell Biology, Baylor College of Medicine, Houston, Texas
Early in his career, Dr. Rudolph pursued biochemical studies on G-protein-mediated signal transduction and generated the first G-protein knockout mouse, which developed ulcerative colitis and adenocarcinoma of the colon. He then applied genetic tools to the analysis of inhibitory neurontransmission in the brain, showing for example that benzodiazepine-induced anxiolysis and sedation are pharmacologically separable, and that commonly used general anesthetics exert their immobilizing action via a specific receptor subtype. Recent studies established circuit-dependent pharmacological functions of GABAA receptors (“circuit pharmacology”), the targets of benzodiazepine drugs. He also contributed to a recent study demonstrating itch suppression in mice and dogs by modulation of spinal GABAA receptors.